Kathleen E Sullivan1. 1. Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. sullivak@mail.med.upenn.edu
Abstract
PURPOSE OF REVIEW: New findings regarding the clinical manifestations and care of patients with DiGeorge syndrome or chromosome 22q11.2 deletion syndrome will be reviewed. Immunologists and primary care providers often are in a position to coordinate the complex care needs of these patients and an awareness of the clinical features is essential. RECENT FINDINGS: DiGeorge syndrome typically occurs in association with a hemizygous deletion of chromosome 22q11.2. Approximately 5-10% of patients with the clinical entity of DiGeorge syndrome do not have the deletion. Recent evidence indicates that the T cell compartment in both patients with the deletion and patients with clinical DiGeorge syndrome without the deletion is less robust than is often indicated by standard T cell enumeration. SUMMARY: This past year has seen a dramatic increase in our understanding of the clinical features of patients with the deletion. Advances in our understanding of the immunodeficiency have been particularly exciting and clinicians should be aware of the characteristics of the immunodeficiency and its changes with age.
PURPOSE OF REVIEW: New findings regarding the clinical manifestations and care of patients with DiGeorge syndrome or chromosome 22q11.2 deletion syndrome will be reviewed. Immunologists and primary care providers often are in a position to coordinate the complex care needs of these patients and an awareness of the clinical features is essential. RECENT FINDINGS:DiGeorge syndrome typically occurs in association with a hemizygous deletion of chromosome 22q11.2. Approximately 5-10% of patients with the clinical entity of DiGeorge syndrome do not have the deletion. Recent evidence indicates that the T cell compartment in both patients with the deletion and patients with clinical DiGeorge syndrome without the deletion is less robust than is often indicated by standard T cell enumeration. SUMMARY: This past year has seen a dramatic increase in our understanding of the clinical features of patients with the deletion. Advances in our understanding of the immunodeficiency have been particularly exciting and clinicians should be aware of the characteristics of the immunodeficiency and its changes with age.
Authors: Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou Journal: Int J Dev Neurosci Date: 2010-10-08 Impact factor: 2.457
Authors: Arpana Rayannavar; Lorraine E Levitt Katz; Terrence Blaine Crowley; Megan Lessig; Katheryn Grand; Elizabeth Goldmuntz; Elaine H Zackai; Donna M McDonald-McGinn Journal: Am J Med Genet A Date: 2018-10-01 Impact factor: 2.802
Authors: P Eberle; C Berger; S Junge; S Dougoud; E Valsangiacomo Büchel; M Riegel; A Schinzel; R Seger; T Güngör Journal: Clin Exp Immunol Date: 2008-11-24 Impact factor: 4.330
Authors: Francis J Mussai; Lea C Cunningham; Geoffrey Rezvani; Constantine A Stratakis; James C Reynolds; Galina Nesterova; Robert M Henshaw; Jason E Levine; Lee J Helman; Diane C Arthur; Su Young Kim Journal: J Pediatr Hematol Oncol Date: 2008-08 Impact factor: 1.289
Authors: Christopher J Haines; Thierry D Giffon; Li-Sheng Lu; Xiaowei Lu; Marc Tessier-Lavigne; Douglas T Ross; David B Lewis Journal: J Exp Med Date: 2009-01-26 Impact factor: 14.307